ACR Incidental Adrenal · Adrenal
Sistemas/Adrenal

ACR Incidental Adrenal ACR incidental adrenal mass management

vigente

Management pathway for incidentally detected adrenal masses based on imaging features and size.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
benign-featuresindeterminatemacroscopic-fatlarge-massprior-malignancy

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor
American College of Radiology
Versão
2017
Ano
2017
Família
achado incidental
Tipo de lógica
flat
Modalidade
CT, MRI
Fonte primária
Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee · doi:10.1016/j.jacr.2017.05.001
Última verificação
2026-06-22
Última checagem
2026-06-22

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Size thresholds and management endpoints pending sourcing.

Mostrar a lógica estruturada (JSON)
{
  "categories": [
    "benign-features",
    "indeterminate",
    "macroscopic-fat",
    "large-mass",
    "prior-malignancy"
  ]
}

Categorias num relance

Cat.SignificadoCondutaRiscoFonte
benign-features
Benign imaging features
Adrenal mass with diagnostic benign imaging features. Unenhanced CT density at or below 10 HU, or signal loss versus spleen between in-phase and opposed-phase chemical-shift MRI, indicates a lipid-rich adenoma at any size. A mass that shows no enhancement (under a 10 HU change between pre- and post-contrast images) represents a cyst or hemorrhage. A benign calcified mass (e.g., old hematoma or granulomatous calcification) also qualifies.
No additional workup or follow-up imaging is needed once benign features are established. The paper also now advises considering biochemical evaluation for most incidentally discovered adrenal masses, acknowledging the literature support for this is limited.
Fig. 1 algorithm; 'Reporting Considerations' (low CT density 10 HU) and 'Overview of the Algorithm' subsection 'Masses With Diagnostic Benign Imaging Features'; 'Adrenal CT Protocol' (nonenhancement defined as <10 HU change)
indeterminate
Indeterminate mass
Mass without diagnostic benign features, indeterminate attenuation (above 10 HU on unenhanced CT), typically 1 to under 4 cm. High-density adenomas above ~20-30 HU on unenhanced CT may stay indeterminate on chemical-shift MRI.
Characterize with a dedicated adrenal CT washout protocol, which assesses density and washout in one exam, or with chemical-shift MRI as an alternative. An absolute washout of 60% or more, or a relative washout of 40% or more when no unenhanced phase is available, indicates an adenoma. If the mass still cannot be characterized and there is no prior imaging or cancer history, 1 to 2 cm masses can be followed at 12 months to confirm stability, and masses over 2 to under 4 cm warrant a dedicated adrenal CT at detection. Stability for a year or more indicates a benign mass needing no further imaging.
Fig. 1 algorithm; 'Overview of the Algorithm' subsection 'Masses Without Diagnostic Features (1 to <4 cm)'; 'Adrenal CT Protocol' (washout formulas and 60% APW / 40% RPW thresholds); 'CS-MRI'
macroscopic-fat
Macroscopic fat (myelolipoma)
Mass containing macroscopic (gross) fat, diagnostic of a myelolipoma; one of the explicitly listed diagnostic benign imaging features (along with cyst and hemorrhage).
No additional workup or follow-up imaging is needed.
Fig. 1 algorithm; 'Reporting Considerations' (macroscopic fat listed as a diagnostic imaging feature); 'Overview of the Algorithm' subsection 'Masses With Diagnostic Benign Imaging Features'
large-mass
Large mass
Isolated adrenal mass 4 cm or larger in size with no benign diagnostic features and no history of cancer.
Surgical resection (without biopsy) is recommended to treat a possible primary adrenal cortical carcinoma; the paper also advises considering biochemical assays to determine functional status and exclude pheochromocytoma before any biopsy or resection.
Fig. 1 algorithm and footnote (1); 'Overview of the Algorithm' subsection 'Masses Without Diagnostic Features (>=4 cm)'
prior-malignancy
Known prior malignancy
Patient with a known malignancy and an indeterminate adrenal mass (no benign diagnostic features / priors), including an enlarging adrenal mass, an indeterminate mass on adrenal CT, or a mass 4 cm or larger.
First refer to available prior imaging to assess stability. A dedicated adrenal CT protocol (without and with contrast) is recommended because contrast-enhanced CT alone cannot reliably separate benign from malignant. If the mass shows central necrosis, is enlarging, remains indeterminate on adrenal CT, or is 4 cm or larger, proceed with PET/CT or image-guided biopsy because the presumed diagnosis is metastatic disease (metastases tend to be more FDG-avid than adenomas, and PET/CT can also detect occult extra-adrenal metastases). Biopsy is reserved predominantly to confirm a suspected metastasis; if pheochromocytoma is suspected, obtain plasma metanephrines/normetanephrines before biopsy.
Fig. 1 algorithm; 'Overview of the Algorithm' subsection 'Masses Without Diagnostic Features (1 to <4 cm)' (cancer history pathway); 'PET/CT' and 'Adrenal Mass Biopsy' sections

Referências cruzadas

fronteira compartilhadaACR Incidental Pancreatic Cyst. ACR incidental pancreatic cyst managementBoth are ACR Incidental Findings Committee white papers in the same series.

Histórico de versões

DataEventoDetalheSituação
2017-08-01publishedACR Incidental Findings Committee adrenal white paper published. evidênciaconfirmado
Quickstart da APIGET /api/v1/systems/acr-incidental-adrenal-2017aberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/acr-incidental-adrenal-2017"
Ver documentação completa →
ACR Incidental Adrenal. ACR incidental adrenal mass management. RadCommons